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Background: ACMG guidelines suggest that clinical laboratories use a variant 
classification system that includes five categories. Some laboratories use their own 
classification systems that divide variants of uncertain significance (VUS) into 
subcategories. There is little literature regarding patient perceived differences among the 
five ACMG categories of variants, and no literature on their perceptions of the 
subcategories of uncertain genetic test results. 
Objective: To determine whether patients perceive differences in different classifications 
of genetic variants, by measuring risk comprehension, risk perception, worry, perceived 
uncertainty, and behavioral intentions. 
Methods: Randomized hypothetical genetic test results were given to each participant 
enrolled in a genome sequencing study. Three categories of variants were presented to 
participants: Variant of Uncertain Significance (VUS), Variant- Possibly Pathogenic 
(VPP), and Variant- Likely Pathogenic (VLP).  
Results: A total of 291 participants completed the survey. Participants perceived risk to 
be higher if they received a VPP or VLP than a VUS, but did not perceive uncertainty 
differently for the variant categories. Behavioral intentions, including screening, sharing 
with family, seeking genetic counseling, and seeking specialty care were found to be 
higher for those who received a VPP as compared to those who received a VUS, but were 
not different between those who received a VPP and a VLP. Participants reported greater 
worry when they received a VPP than when they received a VUS. In addition, worry and 
risk perception were found to partially mediate the relationship between the variant 
classification received and behavioral intentions. 
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Discussion: Our results suggest that sub-classification of uncertain genetic test results 
affects patient perception of risk, worry, and behavioral intentions, but not uncertainty. In 
addition, worry and risk perception partially mediate the relationship between genetic 
variant classification received and behavioral intentions. These findings are important in 
considering guidelines regarding classification systems and can help inform approaches 
to risk communication, which is an important component of genetic counseling. 
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Classification of Genetic Sequencing Variants 
Genetic sequencing is being used increasingly to aid in the identification of the 
underlying genetic etiology of a variety of rare inherited conditions as well as to identify 
the genetic cause of a variety of health conditions that run in families. The ability to 
sequence has outpaced scientists’ ability to interpret the output, so sequencing many 
genes at once often leads to uncertain information. As the technology behind genetic 
sequencing has advanced and its use in clinical and research settings has increased 
greatly, the American College of Medical Genetics and Genomics released updated 
guidelines for the interpretation of sequence variants (Richards 2015). These guidelines 
propose rules for combining criteria to classify sequence variants into one of five 
different classification labels: pathogenic, likely pathogenic, benign, likely benign, or 
uncertain significance. Additionally, despite these recommendations, there is discord 
among genetic testing laboratories regarding the way in which they utilize information to 
classify variants and the classification system and labels that are used. Classification 
labels may be only an internal assignment or may be released to the patient and provider. 
For example, the Johns Hopkins DNA diagnostic laboratory releases its variant 
classifications to the patient and provider and adds a sixth category of variant 
classification: “possibly pathogenic” (DNA Diagnostic Lab at Johns Hopkins 2015). 
There is little research on the meaning of different sub-classifications of variants for 
patients. Research in this area would be useful in guiding future laboratory classification 
policy-making as well as informing providers who will discuss these types of results with 
their patients.   
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Communication about and Patient Reactions to Variants of Uncertain Significance 
 There are currently no clear counseling guidelines for variants of uncertain 
significance, and studies have shown that there is substantial diversity in counselor 
interpretations of variants of uncertain significance (Petrucelli et al. 2002). These 
differences are reflected not only in their interpretations for themselves, but also in the 
dissimilar ways in which this type of result is communicated with the patient. Basic 
guidelines from the National Society of Genetic Counselors (NSGC) suggest that pretest 
counseling should include a discussion of possible test results, which include positive, 
negative, uninformative, and variant of uncertain significance (Daly et al. 2014). These 
recommendations do not include a discussion of specific types of variant classifications 
that laboratories may now be utilizing. 
 Although there is little research on the communication process of the disclosure of 
a variant of uncertain significance, there has been some research on how genetic 
counselors interpret and manage variants. In alignment with practice recommendations, 
Petrucelli et al. (2002) found that 80.1% of counselors surveyed mention variants of 
uncertain significance during pre-test counseling. This study also found that the 
explanations of the meaning of a variant of uncertain significance that counselors provide 
to patients varied, but most counselors stated that a variant of uncertain significance may 
be a disease causing variant or may represent normal variation. A survey of genetic 
counselors by Scherr et al. (2015) found differences in medical management 
recommendations, but that the majority of cancer counselors who receive a variant of 
uncertain significance for their patients provide clinical guidelines based on family 
history, although some report counseling as if the results were pathogenic. 
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Scherr et al. (2015) found that receiving a variant of uncertain significance from a 
genetic testing laboratory is challenging to both genetic counselors and to patients. 
Petrucelli et al. (2002) recognized that just over half of genetic counselors believed that 
their patients understood their test results when given a variant of uncertain significance. 
Several studies have indicated that patients believe variants of uncertain significance are 
difficult to understand and perceive genetic counseling and testing to be less informative 
and reassuring than do patients who receive an uninformative negative result (Richter et 
al. 2013, Culver et al. 2013). Patient interpretation of variants of uncertain significance is 
also extremely varied, with some interpreting that they carried an undetectable gene 
mutation and others believing that their disease diagnosis had no genetic basis (Maheau 
and Thorne 2008). In addition, these individuals demonstrated varying levels of 
uncertainty with regard to their variants of uncertain significance.  
 Additionally, studies have documented that patients have had negative outcomes 
in response to receiving a variant of uncertain significance including higher levels of 
distress about cancer risks due to interpreting the result as a genetic predisposition to 
cancer, and engaging in prevention measures that are not recommended by their provider 
(Vos et al. 2012, Vos et al. 2008, Murray et al. 2011).  O’Neill et al. (2009) reported that 
some women experienced elevated anxiety and distress after disclosure of results that 
persisted for as long as 12 months post-disclosure. Other studies have revealed that many 
women who undergo cancer genetic testing hope for a result that will explain their 
cancer, and thus experience frustration when given a variant of uncertain significance 
(Hallowell et al. 2002, Lodder et al. 2001).  
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Patient Reactions to Genetic Test Results 
 Although research on patients’ reactions to receiving variants of uncertain 
significance is limited, studies have explored how patients react to receiving genetic risk 
information. The focus of genetics research on complex disorders has primarily been on 
the impact of testing individuals and their families and has focused on hereditary forms of 
cancers. As the genetics of complex disorders continues to be better understood and the 
clinical application of genetic testing for these disorders increases, the literature 
published on the implications of genetic testing from the patient perspective has 
expanded. These studies focus on the perceived risk, affective, and behavioral impact of 
undergoing genetic testing and have shown significant effects for each of these outcomes 
















Conceptual Framework for Patient’s Reactions to Uncertain Genetic Information 
 
 Drawing from Mishel’s Uncertainty Theory, the Theory of Planned Behavior, and 
studies on the cognitive and behavioral impact of receiving genetic test results, including 























 One patient outcome of genetic testing that has received recent attention given the 
prevalence of variants of uncertain significance is patients’ perceptions of the uncertainty 
of information. Uncertainty is an important intermediate outcome to study because it is 
theoretically important in the response to a stressful event such as the receipt of a genetic 
test result. Mishel’s uncertainty theory (1988) describes uncertainty as “the inability to 
determine the meaning of illness-related events, occurring when the decision maker is 
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unable to assign definite value to objects or events, or is unable to predict outcomes 
accurately.” Mishel also asserts that health care providers can reduce uncertainty by 
providing information and being confident in their knowledge about the illness, but in the 
case of genetic test results, the provider is increasingly presented with a result that may 
only exacerbate this uncertainty. Han also describes ambiguity as uncertainty arising 
from limits in reliability, credibility or adequacy of available information (Han 2009, 
2014). 
There are several possible sources of uncertainty in a genetic test result including 
the certainty of implication of the specific gene in the mechanism of disease, ambiguous 
pathogenicity of the specific genetic variant, and the possibility of reclassification. The 
number of variants of uncertain significance found are directly correlated with the 
number of genes tested (Domchek et al. 2013, Bombard et al. 2013). The potential for 
reducing uncertainty regarding etiology of a given disease has been discussed as a key 
motivation for undergoing genetic testing, and thus patients may experience ongoing 
negative outcomes when this uncertainty is not reduced following genetic testing (Van 
Asperen et al. 2002). The potential for residual uncertainty after the disclosure of a 
variant of uncertain significance is problematic from the perspective of the Lazarus and 
Folkman’s model of stress and coping (1984) which states that uncertainty makes it more 
difficult to appraise the degree of threat associated with the genetic test result and choose 
a coping response. Von Dijk also points out that simply measuring the levels of distress 
may be an incomplete outcome for understanding the impact of continuing uncertainty 
and ambivalence associated with an inconclusive result. Perceived uncertainty and 
reactions to uncertainty, such as avoidance or tolerance, have been shown to influence 
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health-related behaviors (Han 2009). Genetic variant classifications reflect differences in 
the certainty of the assessment of pathogenicity. Given this and the behavioral 
implications of perceived uncertainty, it is an important outcome to assess in response to 
receiving different genetic test results. 
 
Risk Perceptions 
 Risk perception has been studied as an outcome in many studies of genetic 
counseling as well as specifically in research regarding patient interpretation of variants 
of uncertain significance. Risk perceptions are an individual’s perceived susceptibility to 
a threat and are a key component of many health behavior changes. The expectation in 
many cases is that an individual will use genetic test results to inform behaviors and the 
theory of planned behavior and other theories regarding risk perception and behavior 
would suggest that risk perception is an important part of this process. In this way, risk 
perceptions are an important outcome because they may affect other downstream 
outcomes such as behavior and well-being. There have been many studies that have 
supported the role of risk perceptions in health decision-making. Motivation to forgo 
potentially pleasurable behaviors and engage in inconvenient preventive behaviors 
associated with a disease has been shown to be associated with risk perceptions (Brewer 
et al. 2007). Generally, the higher the risk one perceives, the more likely one is to engage 
in these types of behaviors. This has been very important for health providers who often 
seek to use interventions that successfully engage and change risk perceptions to produce 
increases in health promoting behaviors (Sheeran et al. 2014).  
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  Additionally risk perceptions have also been shown to impact overall well-being. 
Persoskie et al. (2014) found that the effect of cancer on well-being depended upon 
whether people judged themselves to be at low or high risk of cancer. Those who felt 
they were at high risk were found to have a significantly lower life satisfaction and low 
pre-cancer risk perceptions were associated with long-term benefits for well-being.  
 As described above, risk perceptions are important to understanding how 
individuals think, feel, and act regarding genetic risk information, and additionally, 
perception of the risk information may vary based on the way in which it is presented. 
Studies have shown that patients perceive qualitative risk descriptions differently than 
quantitative risk descriptions. Berry et al. (2004) examined people’s interpretation of 
verbal descriptors for risk of medicine side effects and compared these to the numerical 
risks associated with them. This study found that participants significantly overestimated 
side effect risk when given a verbal label to describe this risk, and these differences in 
risk perceptions had an impact on judgments of satisfaction, side effect severity risk to 
health, and intention to take the medicine. Risk perception has been a well-studied topic, 
but the current inability to assign a numeric risk to classification of genetic variants 
makes understanding perceptions of this kind of categorical risk information critical to 
investigate in order to ultimately enhance the effectiveness of genetic counseling and 
genetic testing practice. Generally, genetic testing results have been shown to influence 
risk perceptions. Studies have demonstrated that perceived risk of Hereditary Breast and 
Ovarian Cancer and Hereditary Non-Polyposis Colorectal Cancer in carriers was lower 
12 months posttest compared with before undergoing genetic testing (Claes et al. 2005). 
Studies of patient reactions to variants of uncertain significance have found varying 
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patient perceptions of the risks associated with such genetic variants. One study revealed 
that most patients interpreted their variant of uncertain significance result as indicating a 
high risk of predisposition to cancer and almost half had undergone risk-reducing surgery 
(Vos et al. 2008). Patient risk perceptions have not been studied regarding sub-category 
classifications of variants that some laboratories are currently utilizing or are considering 
utilizing in the future. Because of the implications that risk perceptions can have on well-
being and medical management options, it is crucial to understand this outcome of 
receiving these variant classifications.  
 There are different sub-types of risk perceptions that are important to distinguish 
and assess in response to receiving a genetic test result. Deliberative risk perceptions are 
logical and rule-based and are usually absolute or comparative (Denes-Raj et al. 1994 and 
Tversky et al. 1983). Affective risk perceptions include affect associated with a risk 
(Lowenstein et al. 2001). Both of these types of risk perceptions have been examined in 
the context of genetic testing and have been shown to be important for health behaviors. 
 
Risk Comprehension  
 Risk comprehension in this study refers to the patient’s understanding of the 
objective risk conveyed to them in the results. Studies have shown that there may be 
discordance between risk comprehension and risk perception, therefore an assessment of 
both of these evaluations of risk are important to understand the meaning of variants for 
patients. One study found that some women did not have a match between objectively 
recalled risk and perceived risk of developing breast cancer (Fehinger et al. 2014). In this 
way, it is possible for patients to accurately understand the risk that is presented to them, 
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but to perceive this risk to be lower or higher than the objective risk. Both are important 
in terms of decision-making and engaging in health behaviors.  
Similar to risk perception studies, studies focused on risk comprehension of 
variants of uncertain significance have found significant diversity among patients. In one 
study of inconclusive test results, although women were all given the same letter 
explaining and interpreting their inconclusive test results, some women believed with 
certainty that they carried an inherited mutation, others believed that they did not carry an 
inherited mutation, and others were not even certain about their mutation-carrier status 
(Maheu and Thorne 2008). This difference in understanding of the presented information 
suggests that even standardization of information may not be enough to achieve 
successful risk comprehension, which according to informed choice theory is essential to 
decision-making and health behaviors. Risk comprehension is an important outcome in 
distinguishing between different types of variants, as it is not only a common outcome 
measure in genetic counseling, but has been called into question in the variant of 
uncertain significance results literature as a potential adverse effect by genetic 
counselors. Petrucelli et al. (2002) found that just over half of genetic counselors believed 
that their patients understood their test results when given a variant of uncertain 
significance. Given the confidence expressed by counselors on the success of risk 
communication and the lack of concordant risk comprehension, understanding risk 
comprehension of sub-classifications of variants is important in terms of policy-making 





Behavioral Intentions after Receipt of Genetic Test Results  
 Behavioral intention refers to one of the motivational factors that influence a 
given behavior. The stronger the intention to perform the behavior, the more likely it is 
that the behavior will be performed. The Theory of Planned Behavior (Ajzen et al. 2007) 
predicts an individual’s intention to engage in a behavior at a specific time and place. 
This behavioral intention, in addition to other external factors, is important in the 
prediction of actual behavior. The theory states that behavioral achievement depends on 
both intention and behavioral control. There are six constructs that are proposed to 
interact to produce a behavioral intention: behavioral beliefs, attitude toward the 
behavior, normative beliefs, subjective norm, control beliefs, and perceived behavioral 
control. Actual behavioral control factors play a role in the relationship between intention 
and behavior, and thus behavior as an ultimate outcome in this study does not accurately 
address the research question. Rather, the cognitive components inherent to behavioral 
intentions and its ability to indicate potential actual behaviors serves as an important 
outcome to measure.   
 In addition to the components proposed to interact to produce a behavioral 
intention in the Theory of Planned Behavior, other research has indicated that the other 
outcomes in this study may also impact behavioral intentions. A meta-analysis by 
Sheeran et al. (2014) found that heightening risk appraisals changes both intentions and 
behavior. In addition, Ferrer et al. (2013) found that worry and risk perceptions are 
independently associated with health-promoting behaviors, which demonstrates the 
importance in not only measuring these two constructs as distinct, but for examination of 
the mediating effects produced by these and our other outcome variables. 
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  In the context of genetic testing for some common complex conditions, 
recommended behaviors such as surveillance measures or health-seeking behaviors may 
lead to early detection or prevention of a disease. Several studies have examined behavior 
change in the context of variants of uncertain significance and have found that health 
behaviors after disclosure of this type of result may vary. The majority of these studies 
examined cancer-specific health behaviors and found significant differences in the health 
behaviors between those with a variant of uncertain significance and those with a known 
pathogenic variant. Garcia et al. (2014) found that women with a variant of uncertain 
significance in the BRCA1 or BRCA2 gene had a greater than twofold lower likelihood of 
having risk-reducing surgery than women with a pathogenic variant. Women with a 
variant of uncertain significance were also shown to have statistically lower rates of 
surveillance than women with a pathogenic variant. In this way, health behavior has been 
shown to differ based on receipt of differing variant classifications. There is little 
literature on behavior or behavioral intentions of patients who receive sub-classifications 
of variants. Because there may be other factors that influence actual behavior including 
potential financial or insurance barriers to medical management opportunities, behavioral 
intention will serve to illuminate whether these classifications may elicit differing 
considerations of behavioral change.  
 
Inherited Cardiovascular Risk 
 The majority of current research on patient outcomes when presented with a 
variant of uncertain significance is concentrated in the field of cancer genetics. 
Examining patient outcomes related to variants in inherited cardiovascular disease risk 
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genes would enhance the existing literature on patient outcomes relating to receiving 
variants in complex disease. Similar to cancer-related risks, a cardiovascular risk result 
could provide opportunities for studying recommended health related behaviors such as 
screening, follow-up specialty care, genetic counseling, sharing with family, and lifestyle 
change behaviors and the described cognitive outcomes, as there are screening guidelines 
for some hereditary cardiovascular conditions (Gersh et al. 2011, Priori et al. 2013, 
Lashley et al. 1999). Although similarities exist between cancer and cardiac conditions 
including being common, complex diseases and having some screening options, there are 
unique aspects of cardiovascular disease. For example, cardiovascular disease can cause 
sudden cardiac arrest, which is not an inherent feature of cancer, in which symptoms are 
usually more progressive. The increasing use of panel testing and whole exome 
sequencing in cardiovascular genetics increases the chance of receiving variants of 
uncertain significance. Due to the increasing commonality of such results and the dearth 
of research specific to patient interpretation of variants in this field, it is important to 











Significance of Study 
 The proposed study attempts to fill major gaps in the existing literature regarding 
patients’ reactions to receiving uncertain genetic variants. Although there are existing 
guidelines created by the ACMG for the classification of genetic variants, these 
guidelines were created for the classification of Mendelian disorders and are not intended 
for use in genome sequencing related to common, complex diseases. In addition, there is 
a lack of understanding regarding patient interpretation of the various kinds of uncertain 
classifications in any context. Exploring this in the cardiovascular disease context extends 
the small body of research in cancer-related variants into another context. Currently there 
are striking differences in the ways in which laboratories are utilizing evidence to assign 
classifications to genetic variants, as well as differences in the classification systems that 
these labs use. In this way, major discord exists regarding the information that is 
delivered to the provider and the patient. By better understanding how patients react to 
the commonly used classifications, it may be possible to resolve differences through the 
development of a practice that would benefit patients. While laboratories are attempting 
to classify variants in a way that is meaningful for both the provider and patient, available 
evidence is insufficient to suggest what these classifications mean for patients and 
whether patients distinguish between different classifications. Results from this study 
could guide variant classification system recommendations as well as internal lab 
policies.  
 Historically, research in the return of genetic test results has focused on both 
cognitive and behavioral outcomes. In order to assess whether patients are discerning 
different classifications of genetic variants, it is important to consider a variety of 
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different outcomes. There is evidence that risk perception, risk comprehension, perceived 
uncertainty, and behavioral intentions predict actual patient behavior after receiving 
genetic test results. As behaviors are also influenced by other variables such as financial 
means and social norms, understanding the aforementioned proximal outcomes can 
provide important insight. A better understanding of the outcomes of receiving a genetic 
variant could have a substantial impact not only on the systems used to classify variants, 
but also on genetic counseling practice. As goals of genetic counseling may include 
educating the patient about the nature of a medical disorder, informing the patient of 
available tests, facilitating understanding and meaning-making of the genetic test result, 
and facilitating meaning-making and coping with uncertainty, it is important to first 
understand the impact of results for the patient to better serve their inherent needs. 
Findings from this study will shed light on the impacts of receiving these classifications 
of variants which may highlight further research opportunities for genetic counseling 












Objective and Specific Aims 
This study seeks to assess if patient outcomes of genetic testing (including perceived 
uncertainty, risk perception, risk comprehension, and behavioral intentions) differ based 
on the variant pathogenicity classification that they receive (Variant of Uncertain 
Significance, Variant-Possibly Pathogenic, or Variant- Likely Pathogenic). Participants in 
the ClinSeq® study will be asked to complete a survey to evaluate these outcomes after 
receiving one of these three hypothetical genetic test results.  
 
Aim 1: To assess whether there are any differences in perceived uncertainty, perceived 
risk, risk comprehension, and behavioral intentions based on the hypothetical genetic 
variant classification that is received. 
 
Hypothesis for Aim 1: Participants will have differing outcomes based on the genetic 
variant classification that they receive. Participants who are given a variant of uncertain 
significance are expected to have higher perceived uncertainty than those who have 
received a variant, possibly pathogenic or variant, likely pathogenic. Participants who are 
given a variant, likely pathogenic are expected to have higher risk perceptions, 
comprehend their risk to be higher, and have higher behavioral intentions than those who 
have received a variant of uncertain significance or a variant, possibly pathogenic. 
 
Aim 2: To assess whether worry, risk perception, risk comprehension, or perceived 




Hypothesis for Aim 2: Participant worry, risk perception, risk comprehension and 
perceived uncertainty will mediate the relationship between variant received and 

























This study used a randomized experiment to determine if participants discern differences 
between different classifications of genetic variants. Potential participants were recruited 
from the larger NIH ClinSeq® study. Included individuals must have had completed the 
ClinSeq® Social and Behavioral Baseline Survey and not received genetic results that 
would affect their personal health nor received carrier results that included a variant of 
uncertain significance. 
Participants were recruited by various methods including by phone, by postal mail, and/or 
by secure email. Participants received one of three randomly assigned hypothetical 
genetic test results related to a hypothetical cardiovascular disease through a website and 
then asked to complete an electronic survey. The possible hypothetical test results 
included: “variant of uncertain significance,” “variant-possibly pathogenic,” and “variant-







































Figure 2: Study Design 
 
Study Sample 
Participants were recruited from those already enrolled in the ClinSeq® study at the 
National Institutes of Health in Bethesda, Maryland. The ClinSeq® study is a large-scale 
study that pilots the integration of genome sequencing into clinical research and care to 
assess the technical, medical, and socio-behavioral aspects of implementing this 
technology. Study criteria for enrolling in the ClinSeq® study included being between 45-
65 years old, having not smoked cigarettes in the year prior to study enrollment, living in 
the local area or being willing to return to the NIH campus several times over the years, 
having a primary care physician or access to a community health center, and that 
Recruitment of Eligible Participants from the 
ClinSeq® Study 
Target: 277 participants 
 
Randomization of Pathogenicity of 
Hypothetical Genetic Test Results 



































participants do not have a parent, sibling or child already enrolled in ClinSeq®. The A1 
cohort primarily consists of Caucasian individuals of higher socioeconomic status, who 
have been characterized as early adapters of a new health technology (Lewis et al. 2015). 
Currently, the ClinSeq® study is recruiting an A2 cohort in order to diversify their study 
group, and these targeted individuals are those who self-identify as African-American, 
African or Afro-Caribbean and otherwise meet the outlined study criteria. Because early 
recruitment for the A1 cohort targeted cardiovascular disease risk, participants may have 
a personal or family history of heart conditions as well. Given the availability of both 
cohorts for use in this study, we are expecting a diverse study population. However, 
without representation from all ethnic and socioeconomic groups, the cohort will not be 
reflective of the general population.  Specifically for this study, eligible participants must 
have been consented to be in the larger ClinSeq® study, may not have received any 
genetic results that impact their personal health, and may not have received any carrier 
results that were classified as a VUS. In this way, the participants will have met with the 
genetic counselor prior to having genomic testing and will not have received other results 











Participants received results for a fictional gene associated with an alias condition that 
mimics hypertrophic cardiomyopathy. Each participant received a hypothetical test result 
with a pathogenicity classification of a Variant of Uncertain Significance, Variant- 
Possibly Pathogenic, or Variant- Likely Pathogenic. The other information about the 
hypothetical result was identical for all participants. To increase the reality of the 
hypothetical scenario, the result “report” included a brief description of the disease with 
which the gene is associated, a description of the variant classification system presenting 
a description of all possible types of variants, and screening recommendations for those 
with variants in this gene. In the real world, genetic test results are not received in a 
vacuum; result reports often provide textual framing and genetic counselors or other 
health providers discussing results also provide some context for interpretation. The way 
in which individuals respond to variant categorizations may depend on that context. The 
results template is provided in Appendix A. 
 
Sample Size Calculation 
 Of utmost importance to the study is the ability to detect a significant average 
difference in one outcome measure between individuals who complete the survey with 
results containing different variant classifications. The following sample size calculation 
was performed which involves a multivariate regression with perception of uncertainty as 
the outcome variable. The calculations assume a two-sided hypothesis test with a p-
value<.05 alpha level and a desired power of 80 percent These calculations are applicable 
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to a 2-tailed test, a proportion of sample randomized to treatment as 1/3, and a 
dichotomous independent variable. 
Table 1. Sample Size Required to Achieve 80% Power to Detect Small, Medium, and 












 Effect Size 
Power  
1  101 0.05  7 .3 .5 0.80  
2 124 0.05  7 .3 .45 0.80  
3  157 0.05             7 .3 .4 0.80 
4  204 0.05  7 .3  .35 0.80  
5  277 0.05  7 .3  .30 0.80  
  
 In this study, the target recruitment is 277 participants, powering the study to 
detect relevant relationships among key variables. Drawing from similar work done in the 
ClinSeq® population, a small to moderate effect would indicate a significant and relevant 
contribution of a key variable on the outcome of interest and would provide significant 
evidence that individuals would discern differences between different variant 
classifications (Ferrer et al. 2014). Sung-Woo Cho, of ABT associates, assisted with the 







Risk comprehension was measured using a 7 point scale asking the participant to recall 
the pathogenicity of their genetic test result.  
Risk perception was measured using a scale that includes sub-scales for affective, 
deliberative, and comparative risk perceptions. These risk perception 7 point subscales 
have previously been used in the ClinSeq® population to measure risk perception. This 
scale adapts similar items that have been used in other risk perception studies. The 
instrument assesses affective risk perception by asking participants to rate on a scale of 1-
7, in which 1 is not worried at all and 7 is extremely worried, how worried they are about 
3 specific outcomes of the genetic testing: that the genetic finding puts them at an 
increased risk for developing heart disease, that their existing health condition is caused 
by this genetic change, and that their relatives could be affected by the genetic condition. 
The instrument assesses deliberative risk perception by asking participants to rate how 
likely they feel associated risks are related to the genetic test result. Comparative risk 
perceptions are assessed by asking participants the items presented in the deliberative risk 
questions but in the context of comparing oneself with other people of the same age and 
sex on a scale from 1-7 where 1 is much less likely than the average person and 7 is much 
more likely than the average person.  
Worry was measured using the same survey questions used in the Baseline Survey of 
ClinSeq® study, with adapted syntax to address worry regarding the given results. This 
scale assess worry using a 7 point scale. 
Perceived uncertainty was measured using the 8-item Personal Uncertainty in Genomic 
Sequencing (PUGS) Scale (Biesecker et al. 2015). This scale assesses uncertainty using a 
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rating system of 1-5 with 1 being very uncertain and 5 being very certain with relation to 
personal uncertainty in three domains: clinical, affective, and credibility. This scale has 
been utilized in the ClinSeq® population to assess anticipated uncertainties related to 
genome sequencing. There is evidence for the scale’s convergent validity, as use of the 
scale in this population showed significant correlations with perceived ambiguity and 
attitudinal ambivalence. In addition, responses to the PUGS scale were normally 
distributed and had high internal consistency (α=.835). Biesecker and colleagues (2015) 
propose a slightly modified version of the scale for use after receipt of genome 
sequencing results. This modified version of the PUGS Scale removes the word “future” 
but leaves the stem of each item in most cases. The modified PUGS Scale is used to 
assess perceived uncertainty in this study by summing and averaging all items in this 
scale to generate an overall uncertainty score as well as sub-scores in three domains: 
clinical, affective, and credibility.  
Behavioral intentions were measured using the same survey questions used in the 
Baseline Survey of the ClinSeq® study which uses a 7 point scale to assess the likelihood 
that an individual will engage in each of the following behaviors: changing lifestyle, 
undergoing screening, seeking genetic counseling, sharing the results with family 
members, and seeking specialty care (Facio et al. 2013). 








All analyses were completed using STATA version 13. Means, standard deviations, 
medians, and frequency distributions were calculated for univariate variables. The 
different types of variants received were coded as dummy variables, with 1representing a 
VUS, 2 representing a VPP, and 3 representing a VLP. To compare means, regression 
and post-hoc Tukey tests were used. In order to assess for mediation, the Sobel-Goodman 
test was used. All of the variables were treated as continuous variables.  
 
Ethics statement 
This research was reviewed and approved by the National Human Genome Research 
Institute Institutional Review Board at the National Institutes of Health. Participants 
signed written informed consent for the overall protocol at the time of enrollment and 
indicated their consent for this specific ancillary study by checking a box on the online 
survey which was approved by the National Human Genome Research Institute 
Institutional Review Board. Participants were also sent out a letter after the completion of 
the survey to thank them for participating and remind them that the results included in 
this study were hypothetical and did not represent their true genetic results. Survey data 










The response rate for the completion of the survey was 290 out of 490 contacted (59%). 
Of the respondents that completed the survey, 63% were from the A1 cohort. 54% of 
respondents were female. 58% of respondents were married, 21% were single, 10% were 
divorced, and 4% were widowed or reported their relationship status as other. 63% of 
respondents reported income greater than $100,000 per year, 14% reported income 
between $75,000-$100,000, 10% reported income between $50,000-$74,999, 5% 
reported income between $25,000-$49,999, and 3% reported income less than $25,000 
per year.  
 
Worry, Risk Comprehension, Risk Perception, and Behavioral Intentions 
In order to assess whether these outcomes differed by variant classification received, 
regressions were done and post-hoc Tukey tests were conducted for each pair of variant 
classifications. Significance was established at p<.05 for all of the post-hoc tests. 
Worry  
As predicted, and as seen in Table 2, there was a main effect of condition such that worry 
increased with increasing pathogenicity of the genetic test results. Worry was statistically 
different for all pairs of variants received. Mean worry for participants who received a 
VLP was 4.14, mean worry for participants who received a VPP was 3.34, and mean 






Table 2: Worry  
Variant Received Mean 
Variant of Uncertain Significance  (VUS) 2.77a 
Variant- Possibly Pathogenic (VPP) 3.34b 
Variant- Likely Pathogenic (VLP) 4.14c 
Different subscripts a,b,c indicate that the means were statistically significantly different (p<.05) 
 
Risk Comprehension 
Similarly, there was a main effect of condition on risk comprehension, which was highest 
in the VLP condition followed by VPP and, in turn, risk comprehension was higher for a 
VLP than a VPP and a VLP than a VUS. The difference in risk comprehension between a 
VUS and a VPP was not statistically significant. 
Table 3: Risk Comprehension 





Absolute Risk Perception 
People in the VLP condition perceived significantly higher risk than in the other two 







Table 4: Absolute Risk Perception 





Comparative Perceived Risk 
People in the VLP condition perceived  significantly higher risk as compared to similar 
individuals than in the other two conditions (VUS and VPP), which did not differ from 
each other.  
Table 5: Comparative Perceived Risk 





Experiential Perceived Risk 
Experiential risk perception increased with increasing pathogenicity of the variant 
received. Experiential risk perception was statistically different for pairs of variants 
received. Mean experiential risk perception for participants who received a VLP was 
5.20, mean experiential risk perception for participants who received a VPP was 4.38, 





Table 6: Experiential Perceived Risk 






PUGS score was significantly higher for those who received a VLP compared to those 
who received a VUS. PUGS scores for those who received a VUS vs. VPP or VPP vs. 
VLP were not significantly different.  
Table 7: PUGS Score 






Clinical uncertainty was significantly higher for those who received a VLP compared to 
those who received a VUS. Clinical uncertainty was not significantly different for a VUS 






Table 8: Clinical Uncertainty 






Affective uncertainty was significantly higher for those who received a VLP compared to 
those who received a VUS, but was not statistically significant for VUS vs. VPP or VPP 
vs. VLP. 
Table 9: Affective Uncertainty 






Differences in credibility were not statistically significant for comparisons of any of the 
variant classification groups. 
Table 10: Credibility 









Intentions to screen were significantly lower for those who had received a VUS as 
compared to the other conditions (VPP and VLP) which did not differ from each 
other.  
 Table 11: Intentions to Screen 






Seek Genetic Counseling 
Intentions to seek genetic counseling were significantly higher for those who 
received a VLP as compared to a VPP and for those who received a VLP 
compared to a VUS. Intentions to seek genetic counseling for those who received 
a VPP were not statistically significant from those who received a VLP. 
 Table 12: Intentions to Seek Genetic Counseling 









Share With Family 
Intentions to share the result with family were significantly higher for those who 
received a VLP as compared to a VPP and for those who received a VLP 
compared to a VUS. Intentions to share the result with family for those who 
received a VPP were not statistically significant from those who received a VLP. 
 Table 13: Intentions to Share With Family 





Seek Specialty Care 
Intentions to seek specialty care were significantly higher for those who received 
a VLP as compared to a VPP and for those who received a VLP compared to a 
VUS. Intentions to seek specialty care for those who received a VPP were not 
statistically significant from those who received a VLP. 
 Table 14: Intentions to Seek Specialty Care 









Intentions to change lifestyle increased with increasing pathogenicity of the 
classification of the variant received. Intentions to change lifestyle were 
statistically different for all of the variants received. Mean intention to change 
lifestyle for participants who received a VLP was 5.93, mean intention to change 
lifestyle for participants who received a VPP was 5.28, and mean intention to 
change lifestyle for participants who received a VUS was 4.46. 
 Table 15: Intentions to Change Lifestyle 






To assess for mediation, an approach based on Baron and Kenny was used. First, as 
discussed above, regressions with post-hoc tests indicated variant classification received 
affected the behavioral intentions of participants. In addition, regressions with post-hoc 
tests indicated that variant classification received affected participant worry, risk 
perception, and risk comprehension. Next, analyses were re-done to test if variant 
classification received affected participant behavioral intentions while controlling for the 
other outcomes individually. The Sobel test was conducted to determine whether the 
decrease in the beta coefficient is significant.  
As expected, both worry and risk perception were found to mediate the relationship 




Worry mediated the relationship between variant classification received and all 
behavioral intentions measured (p<.05).  


































































The first number in the table refers to the Sobel value and the number in parentheses is the corresponding p 




Absolute Risk Perception 
Absolute risk perception mediated the relationship between variant classification received 
and most of the behavioral intentions measured, except when comparing differences 
between VUS and VPP. In addition, intentions to share with family did not differ when 
controlling for absolute risk perception in the VPP v VLP comparison. 























































Comparative Risk Perception 
Comparative risk perception mediated the relationship between variant classification 
received and all of the behavioral intentions measured (except for the comparison 
between VUS and VPP).  




















































Experiential Risk Perception 
Experiential risk perception mediated the relationship between variant classification 
received and all of the behavioral intentions measured (p<.05) 





















































Risk comprehension mediated the relationship between variant classification received 
and most behavioral outcomes (except for the comparison between VUS and VPP). 
36 
 
Intentions to seek genetic counseling and intentions to share with family did not differ for 
the comparison of VPP and VLP when holding risk comprehension constant.  






















































PUGS Score very slightly mediated the relationship between variant classification 
received and behavioral outcomes only when comparing VUS and VLP.  






















































Our 7 point outcome scales included a separate ‘uncertain’ category. For the purpose of 
analyses, the uncertain responses were treated as separate from the other rankings and 
were removed for all regression and statistical analyses.  
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Risk Comprehension:  26% (22/85) of participants who received a VUS were 
uncertain of risk comprehension. 5% (5/93) of participants who received a VPP were 
uncertain of risk comprehension. 4.5% (5/111) of participants who received a VLP were 
uncertain of risk comprehension. The number of uncertain responses in risk 
comprehension for a VUS is significantly higher than what would have been expected 
according to the null hypothesis (χ2=43.78, p<.05). 
Absolute Risk Perception: 20% (17/85) of participants who received a VUS were 
uncertain of absolute risk perception. 2.2% (2/93) of participants who received a VPP 
were uncertain of absolute risk perception. 2.7% (3/111) of participants who received a 
VLP were uncertain of absolute risk perception. The number of uncertain responses in 
absolute risk perception for a VUS is significantly higher than what would have been 
expected according to the null hypothesis (χ2=24.29, p<.05) 
Comparative Risk Perception: 17.6% (15/85) of participants who received a VUS 
were uncertain of comparative risk perception. 12.9% (12/93) of participants who 
received a VPP were uncertain of comparative risk perception. 10.8% (12/111) of 
participants were uncertain of comparative risk perception. Although there were more 
uncertain responses across each variant category for comparative risk perception than any 
other outcome, the number of uncertain responses for each variant category is not 
statistically different from expected according to the null hypothesis (χ2=1.91, p<.05) 
Behavioral Statistics: 6 total participants did not answer any of the behavioral 
output questions after receiving a hypothetical genetic test result. Of these, 2 had received 
a VUS, 1 had received a VPP, and 3 had received a VLP. 
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Change Lifestyle: 1.2% (1/83) of participants who received a VUS were uncertain 
of their intentions to change lifestyle. 0.9% (1/108) of participants who received a VLP 
were uncertain of their intentions to change lifestyle. 
Screening: 2.4% (2/83) of participants who received a VUS were uncertain of 
their intentions to participate in screening. 1 participant who received a VLP did not 
respond to this question. 
Specialty Care: 1.2% (1/83) of participants who received a VUS were uncertain of 
their intentions to obtain specialty care. 3.3% (3/92) of participants who received a VPP 
were uncertain of their intentions to obtain specialty care. 1 participant who received a 
VLP did not respond to this question. 
Share With Family: 2.2% (2/92) of participants who received a VPP were 
uncertain of their intentions to share the result with family members. 1 participant who 
received a VUS and 1 participant who received a VLP did not respond to this question.  
Seek Genetic Counseling: 1.2% (1/83) of participants who received a VUS were 
uncertain of their intentions to seek genetic counseling. 1.1% (1/92) of participants who 
received a VPP were uncertain of their intentions to seek genetic counseling. 2 
participants who received a VLP did not respond to this question. 
Table 22: Uncertainty and Nonresponses of Behavioral Intentions 
Behavioral 
Intention 
VUS VPP VLP 
Change Lifestyle 1 0 1 
Screening 2 0 *1 
Specialty Care 1 3 *1 
Share With 
Family 
*1 2 *1 
Seek Genetic 
Counseling 
1 1 *2 
*indicates did not answer the question 
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Integrating Uncertain Responses 
To ensure that omission of uncertain responses did not have an appreciable effect on the 
findings, we also conducted the analysis in a way that integrated these responses.   In 
particular, the uncertain responses were converted into 4’s on the 7-point Likert scales. 
For the majority of outcomes, the results remained identical.  The only exception was that 
the difference in the means for absolute risk perception when receiving a VUS vs. a VPP 
became statistically significant. Thus, the findings are robust with respect to the inclusion 
or omission of uncertain responses. 
 
Table 23: Absolute Risk Perception With Uncertain Responses Included 






Table 24: Risk Comprehension With Uncertain Responses Included 










Table 25: Comparative Risk Perception With Uncertain Responses Included 

























The main goal of this study was to assess whether individuals discern differences 
between different classifications of uncertain genetic variants. To that end, we provided 
hypothetical genetic test results to participants in the NIH ClinSeq® study. Each 
participant was randomized to receive a Variant of Uncertain Significance (VUS), a 
Variant- Possibly Pathogenic (VPP), or a Variant- Likely Pathogenic (VLP) and then we 
measured risk comprehension, risk perception, worry, perceived uncertainty, and 
behavioral intentions. We found that participants cognitively and emotionally 
distinguished the three different genetic variant classifications, although cognitively they 
appeared to construe VPP more like a VUS. Interestingly, despite these differences, 
participants who received a VPP intended to behave as if they received a VLP. 
Risk Comprehension 
 Participants who received a VLP had a higher risk comprehension score than 
those who received a VPP (p<.05). Similarly, participants who received a VLP had a 
higher risk comprehension score than those who received a VUS. The difference in the 
mean risk comprehension score between those who received a VUS and a VPP was not 
statistically significant.  
 Risk comprehension was found to be difficult for participants to answer when 
they received a VUS, as compared to the other options. 26% of participants who received 
a VUS were “uncertain” of their risk comprehension (χ2=43.78).  This finding 




 Risk comprehension slightly mediated the relationship between variant received 
and behavioral intentions for all behavioral intentions when comparing VUS v VLP. It 
also was found to be mediate the effects of VPP v VLP for Overall Behavior Score, 
intentions to change lifestyle, intentions to screen, and intentions to seek specialty care, 
but not for intentions to share with family or intentions to seek genetic counseling. 
Risk Perception 
 Absolute Risk Perception 
 Those who received a VLP perceived absolute risk to be higher than those who 
received a VPP or a VUS. The difference in absolute risk perception between those who 
received a VUS and those who received a VPP was not statistically significant. When the 
“uncertain” responses were re-classified as 4’s on the 7 point likert scales, this difference 
did become statistically significant. In this way, participants cognitively perceived risk to 
be higher as pathogenicity increased.  
 20% of participants who received a VUS were “uncertain” of absolute risk 
perception. This was found to be significantly higher than what would have been 
expected (χ2=43.78). This finding echoes the result for risk comprehension and furthers 
the point that participants have a difficult time understanding their risk when they receive 
a VUS. Absolute risk perception mediated the relationship between variant received and 
behavioral intentions, except when examining a VUS v. VPP which was not statistically 
significant. 
 Comparative Risk Perception 
 Comparative risk perception followed the same pattern as absolute risk 
perception. Those who received a VLP perceived risk to be higher as compared to others 
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than those who received a VPP or a VUS. The difference in comparative risk perception 
between those who received a VUS and those who received a VPP was not statistically 
significant. When “uncertain” responses were included in the analyses, the findings 
remained the same.  
 17.6% of participants who received a VUS, 12.9% of those who received a VPP, 
and 10.8% of those who received a VLP were “uncertain” of their perceptions of risk 
when compared to others. These findings suggest that this outcome is more difficult to 
assess for our participants regardless of variant received.  
 Comparative risk perception mediated the relationship between variant received 
and behavioral intentions, except when examining a VUS v. VPP which was not 
statistically significant.  
 Experiential Risk Perception 
 Experiential risk perception scores increased across all variant categories with 
increasing pathogenicity of the classification of the variant. Participants felt that their risk 
was highest for a VLP and lowest for a VUS. In contrast to absolute and comparative risk 
perception questions, all participants, regardless of variant classification received, 
answered the experiential risk perception questions on the 7 point likert scale without 
indicating that they were “uncertain.”  This seems to suggest that people have a better 
“gut feeling” about their risk levels than they do about their actual absolute or 
comparative risk. 
 In addition, experiential risk perception was found to partially mediate the 
relationship between variant received and behavioral intentions for all variant 




Worry increased across all variant categories with increasing pathogenicity of the genetic 
test results; participants who received a VLP were the most worried and participants who 
received a VUS were the least worried. Worry mediated the relationship between variant 
received and behavioral intentions across all variants received and for all behavioral 
intentions. In addition, no participants marked “uncertain” for the items related to the 
scale for worry when they received any of the three variants.  
 
Behavioral Intentions 
In general, participants indicated that they had a high desire to change behaviors after 
receiving genetic test results, with means relatively high in all conditions. Nevertheless, 
intentions to change lifestyle increased across the variant categories with increasing 
pathogenicity of the classification of the variant received. Intentions to screen, intentions 
to seek genetic counseling, intentions to share the result with family, and intentions to 
seek specialty care were lower for those who received a VUS than those who received a 
VPP or VLP. In addition, participants who received a VPP had higher intentions than 
those who received a VUS. On the other hand, there was no difference in behavioral 
intentions between those who received a VLP and those who received a VPP. This 
indicates that in regards to intention to screen, seek genetic counseling, share the result 
with family, and seek specialty care, participants who received a VPP would behave 
differently than those who received a VUS. In fact, they would intend to behave as if they 





Participants perceived greater certainty for a VLP than a VUS. Differences in perceived 
uncertainty were not statistically significant for a VUS v. VPP or a VPP v. VLP. This 
finding was consistent for the subscales of Clinical Uncertainty and Affective 
Uncertainty. No differences were found between any variant classification for credibility. 
Perceived uncertainty was only found to partially mediate the relationship between VUS 
v. VLP and behavioral intentions. These results are striking, as variant classifications are 
in and of themselves representations of uncertainty regarding their clinical and 
phenotypic meaning.  
 
Clinical Implications 
These results have implications for guidelines and practices regarding the classification 
of genetic variants as well as for practitioners such as genetic counselors who may return 
such results to patients or participants. Although variant classification systems are 
designed to communicate the level of certainty regarding the meaning of the genetic 
change, it is clear that this is not understood in sub-classifications of uncertain genetic 
results. Participants perceive a VLP as more certain than a VUS, but do not perceive 
uncertainty differently between further sub-classifications of uncertain results. It is 
therefore important to consider the purpose of further sub-classifications of results. While 
they do not distinguish uncertainty between sub-classifications of uncertain genetic test 
results, the results demonstrate that participants understand and feel risk differently 
between sub-classifications of uncertain genetic test results. When given a VPP, 
participants intended to behave as if they had received a VLP. Although these outcomes 
46 
 
included relatively low-risk behavior changes, other outcomes for genetic conditions can 
include behaviors such as prophylactic surgical options which can carry much more 
significant risks. Guidelines should consider that individuals would intend to behave as if 
they had received a genetic variant that conveys more certainty and in practice such 
behavioral changes are commonly considered. 
 In addition, prior to this study, little was known about how individuals experience 
these sub-classifications of genetic test results. As more laboratories are using or 
considering implementing similar variant sub-classifications, providers may have to 
return such results to patients. It has been shown in other studies that providers who are 
familiar with genetic testing and returning genetic test results are very uncomfortable 
with uncertain genetic results. This study offers those providers information regarding the 
ways in which individuals understand those results. These findings may be important in 
facilitating such results disclosures, as they encourage providers to understand not only 
the difficulty that the individual may have in understanding and processing risk, but 
additionally allows for positive interventions regarding reduction of worry and 
facilitating a discussion around behavior intentions. In this way, reducing potential 
increases in worry from a sub-classification of uncertain result and discussing and 
making sure behavioral intentions are appropriate for that finding may facilitate better 







Strengths and Limitations of the Study 
This study contributes to the tremendously lacking field of patient understanding of 
genetic test results. There are no currently published studies that examine patient 
outcomes when given different sub-classifications of uncertain genetic test results, yet 
there are already guidelines and current practices regarding these findings.  
 Despite the novelty of the design and findings, there are several limitations of this 
study that are worth noting. First, members of the ClinSeq® study cohort, may not be 
representative of the larger population or of a clinical population. Future studies should 
attempt to accrue a more diverse population to establish generalizability.  In addition, the 
genetic test results given to participants were hypothetical. Although the population had 
received pre-test counseling and was familiar with genetic test results, the outcomes may 
have differed if participants had been given real test results. Further studies that follow 
patients who receive real genetic test results may clarify whether these participants 
reacted in a way consistent with real results. Similarly, participants were surveyed 
regarding their behavioral intentions. Longitudinal studies would be beneficial in 










Areas of Future Research 
This study is one of the first to assess individual outcomes of receiving uncertain genetic 
variant classifications. Future studies should attempt to reproduce these outcomes in a 
more diverse clinical cohort using real genetic test results. In addition, future studies 
should consider using longitudinal methods to assess actual behavior over time. This 
study examined the sub-classifications of uncertain genetic test results in the context of a 
fabricated cardiovascular condition. Future studies should examine these results in 
different health contexts including across different clinical specialties and with differing 


















This is one of the only studies to assess individual outcomes of receiving sub-
classifications of uncertain genetic variants. No previous studies have investigated the 
implications of increasing genetic variant classifications beyond the recommended 5 
result classifications. Although these further sub-classifications would serve to indicate 
differing levels of certainty regarding the implications of the change, we found that 
participants did not perceive uncertainty differently between the sub-categories of genetic 
variants. Participants perceived risk differently between a VPP and VLP, but in some 
measures did not perceive risk differently between a VUS and VPP. Participants reported 
increased worry with increased pathogenicity. Participants who received a VPP differed 
in their behavioral intentions from those who received a VUS, and intended to behave as 
if they had received a VLP. These findings are important for guidelines regarding variant 
classification systems and highlight examination of the reason behind and consistency in 
patient outcomes of creation of further sub-classifications of variants. In addition, these 
findings can help providers such as genetic counselors by informing approaches to risk 
communication and other important aspects of counseling for individuals who receive 
these types of results. Further studies involving actual clinic genetic test results would be 
useful in confirming these findings. It would also be reasonable for further studies to 
encompass a more representative sample of the national population and to use 
longitudinal methods to assess behavioral outcomes. The findings presented here are of 
fundamental importance to increasing knowledge regarding individual interpretation and 
use of sub-classification of uncertain genetic test results and have implications for 
establishment and improvement of guidelines regarding these types of results as well as 
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implications for providers who may return these types of result classifications to patients. 
It is important to understand how patients construe uncertainty to be effective at genetic 
risk communication, and studies like this are crucial to attain. Given the findings 
presented here, further expansion of the genetic variant classification system is likely to 
be of limited utility for patients and may cause unintended risk perceptions, affective 
































Appendix A: Survey Instrument Difference? 
You are invited to participate in a study conducted by researchers at Johns Hopkins University and 
the National Human Genome Research Institute. 
 
Why is this study being done? To learn more about how participants understand their genetic test 
results. (The test results you receive today are hypothetical and do not reflect actual results). 
 
Why am I being asked to take part in this study? We are interested in hearing from individuals who 
are participating in genetic testing research studies. You can take part in this study if you already 
agreed to participate in the larger ClinSeq® study. 
 
What is involved in this study? There is one survey that takes up to 30 minutes to finish. The survey will 
ask you to read and respond to a hypothetical genetic test result. If completing the survey makes you feel 
uncomfortable, you can stop completing the survey at any point. If you feel uncomfortable after completing 
the survey, and do not want your responses to be included in the study, you may contact the researcher to 
indicate this preference using the contact information provided below. 
 
Are there any benefits to taking part in the study? You will not directly benefit from taking part in this study. 
However, the information you provide may help to improve genetic testing services for others in the future. 
 
Do I have to take part? You do not have to be a part of this study if you do not want to. You can stop taking 
this survey at any time. You can choose to skip any question that you do not wish to answer. Choosing not 
to participate will not affect your participation in the ClinSeq® study. 
 
Who else will know that I am in the study? Your answers to this study will not be part of any 
medical record. When we report our research results it will be done without identifiable information 
from individual participants. 
 
Will I be told about the findings in the study? We will provide the general findings of this study in the 
ClinSeq® participant newsletter. 
 
Problems or Questions? If you have any problems or questions about this study or about your rights as a 
participant, please contact the researchers (contact information below). 
 
Lydia Hellwig, BS     William Klein, PhD 
Genetic Counseling Graduate Student   Associate Director 
JHU/NHGRI Genetic Counseling Program   Behavioral Research Program 
(414) 204-0611     National Cancer Institute 
 
Katie Lewis, ScM, CGC 
Genetic Counselor, ClinSeq® 
Genetic Disease Research Branch 
(301) 594-3063 
 
* 1. Please check the box below if you have read and understood the information 
provided to you about the study. 





Before completing this survey, please make sure you agree to the potential risks and benefits of 
participation as outlined in the consent form above. 
 
STATEMENT OF CONFIDENTIALITY: All of the information that you provide in the survey will be kept 
confidential. The information that you provide will be used for research purposes only. The information that 
you provide will not be released to anyone other than the researchers of this study. Completion of this 
survey is completely voluntary. 
 
* 2. Please enter your Custom  ID 































Now imagine that you have received the following genetic sequencing results. Please 
take a few minutes to go over these results. 
 















Cardiopraevaris Disease is a condition that disrupts the way the heart normally functions. People with this 
condition have extra tissue that continues to build up in the heart over the lifespan. This makes it hard for 
the heart to do its normal job of pumping blood to the rest of the body. All people with this condition have 
certain symptoms, and if left untreated some of these symptoms may be very severe. 
These symptoms include: 
 
· Chest pain 
· Shortness of breath 
· Feeling unusually tired 
· Heart palpitations 
· Fainting 
· Dizziness 
· Sudden cardiac death 
· Stroke, which is a condition that happens when the brain does not get enough blood. Symptoms of a 
stroke vary depending on what area of the brain is affected, but can include: trouble with walking, difficulty 
speaking or understanding what others say to you, paralysis or numbness of the face, leg or arm, or 
trouble with your vision. 
 
Both genetics and environment can influence the development of Cardiopraevaris Disease. Symptoms 
may be triggered by exercise, strong emotions, certain medications, caffeine, lack of sleep, or alcohol. 
 
Once a person has been diagnosed with Cardiopraevaris Disease, certain tests should be done to monitor 
heart function. Those might include tests to look at the electrical signals in your heart, such as an 
electrocardiogram (EKG) or Holter monitoring. They might also include tests to look at the structure and 
function of the heart, such as an echocardiogram. Follow-up with a doctor is important to prevent more 
serious symptoms from developing. In addition, if you are found to have a genetic change that causes 
Cardiopraevaris Disease, it is recommended that you speak with your genetic counselor and share these 
results with your family members. 
 
*4. Based on the information you received as your test result, please answer 



















































        
 
*6. Now answer the same question about how likely it is that your results mean the 




























        
 






















































*8 Rate how strongly you agree with the following statements 













I feel like 
my genetic 
change 












    









        












*9 Rate how uncertain you are about the following aspects of your sequence results on a 
scale from 1 to 5 with 1 being very uncertain and 5 very certain. 
 
 1  
Very Uncertain 
 
2 3 4 5 
Very Certain 
What my test 
results may 









What actions I 
need to take 
based on my test 
results 
     
How my 
physician may 
use my results to 
improve my 
health 
     
Whether to be 
worried or 
concerned about 
my test results 
     
Whether to be 
alarmed about 
my test results 
 
  
    
Whether my test 
results will 
disrupt my life 
     
Whether I can 
trust my test 
results 
 
     













*10. Please rate how likely you feel you would be to do the following based on these 















How likely is it 










    
How likely is it 
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screening? 
        
How likely is it 




        
 
 
How likely is it 
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Now you will receive a genetic test result that is NEW and DIFFERENT than 
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electrocardiogram (EKG) or Holter monitoring. They might also include tests to look at the structure and 
function of the heart, such as an echocardiogram. Follow-up with a doctor is important to prevent more 
serious symptoms from developing. In addition, if you are found to have a genetic change that causes 
Cardiopraevaris Disease, it is recommended that you speak with your genetic counselor and share these 
results with your family members. 
 
*11. Based on the information you received as your test result, please answer 


















































        
 
*13. Now answer the same question about how likely it is that your results mean the 




























        
 























































*15. Rate how strongly you agree with the following statements 
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*16. Rate how uncertain you are about the following aspects of your sequence results on 
a scale from 1 to 5 with 1 being very uncertain and 5 very certain. 
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*17. Please rate how likely you feel you would be to do the following based on these 
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Now you will receive a genetic test result that is NEW and DIFFERENT than 
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Cardiopraevaris Disease is a condition that disrupts the way the heart normally functions. People with this 
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electrocardiogram (EKG) or Holter monitoring. They might also include tests to look at the structure and 
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*13. Now answer the same question about how likely it is that your results mean the 




























        
 
























































*15. Rate how strongly you agree with the following statements 
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*16. Rate how uncertain you are about the following aspects of your sequence results on 
a scale from 1 to 5 with 1 being very uncertain and 5 very certain. 
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17. Please rate how likely you feel you would be to do the following based on these 
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Thank you for your participation! 
 
As a reminder, these genetic test results were not related to and do not in any way reflect 











Follow-Up Letter to Participants
 
 




Thank you for your recent participation in a survey conducted by researchers at the Johns 
Hopkins University and the ClinSeq® project. The purpose of this study was to learn 
more about your thoughts about receiving certain imaginary genetic testing results. The 
information you provided may help to improve our understanding of the patient’s 
perspective and ultimately, this may improve genetic testing services in the future.  
 
This study involved filling out one survey. The survey asked you to read an imaginary 
genetic test result form and respond as if you had actually received these results.  We are 
sending you this letter to remind you that the genetic testing results you saw in the 
survey were not real and do not in any way reflect your actual results from your 
participation in the ClinSeq® study. 
 
If you have any further questions about this study, please contact us at 301-443-6160. 
Thank you for your time and participation in this survey. We look forward to learning 




         
 
Lydia Hellwig, BS      William Klein, PhD 
Co-investigator      Associate Director 
Genetic Counseling Graduate Student   Behavioral Research Program 
JHU/NHGRI Genetic Counseling Program   National Cancer Institute 
     
Katie Lewis, ScM, CGC       
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